Finch Therapeutics to Participate in Upcoming June Investor Conferences
Finch Therapeutics to Participate in Upcoming June Investor Conferences
SOMERVILLE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will participate in fireside chats at the following investor conferences:
- Jefferies Healthcare Conference on Friday, June 10, 2022 at 8:00 am ET in New York, NY
- JMP Securities Life Sciences Conference on Wednesday, June 15, 2022 at 2:00 pm ET in New York, NY
Live webcasts of the fireside chats will be available under the "Investors & News" section of the Finch website and will be archived for approximately 30 days following each event.
About Finch Therapeutics
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch's lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. Finch is also developing FIN-211 for children with autism spectrum disorder and significant gastrointestinal symptoms. Finch has a partnership with Takeda focused on the development of targeted microbiome therapeutics for inflammatory bowel disease. Finch routinely posts information that may be important to its investors on its website at . Finch encourages investors to consult the "Investors & News" section of its website regularly.
Human-First Discovery® is a registered trademark of Finch Therapeutics Group, Inc.
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com
Media Contact:
Jenna Urban
Berry & Company Public Relations
(212) 253-8881
jurban@berrypr.com
SOMERVILLE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. ("Finch" or "Finch Therapeutics") (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will participate in fireside chats at the following investor conferences:
麻塞諸塞州薩默維爾，2022 年 6 月 2 日（全球美通社）-芬奇治療集團有限公司（「芬奇」或「芬奇治療」）（納斯達克股票代碼：FNCH），利用其臨床階段微生物組治療公司 以人為本的發現® 開發一類新型口服生物藥物的平台，今天宣布，首席執行官 Mark Smith 博士將在以下投資者會議上參加爐邊聊天：
- Jefferies Healthcare Conference on Friday, June 10, 2022 at 8:00 am ET in New York, NY
- JMP Securities Life Sciences Conference on Wednesday, June 15, 2022 at 2:00 pm ET in New York, NY
- 富瑞醫療保健會議將於 2022 年 6 月 10 日星期五上午 8:00 在美國東部時間紐約舉行
- JMP 證券生命科學會議將於 2022 年 6 月 15 日星期三下午 2:00 在美國東部時間紐約市舉行
Live webcasts of the fireside chats will be available under the "Investors & News" section of the Finch website and will be archived for approximately 30 days following each event.
爐邊聊天室的即時網路直播將在芬奇網站的「投資者與新聞」版面下提供，並將在每次活動結束後約 30 天內存檔。
About Finch Therapeutics
關於芬奇治療
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch's lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. Finch is also developing FIN-211 for children with autism spectrum disorder and significant gastrointestinal symptoms. Finch has a partnership with Takeda focused on the development of targeted microbiome therapeutics for inflammatory bowel disease. Finch routinely posts information that may be important to its investors on its website at . Finch encourages investors to consult the "Investors & News" section of its website regularly.
芬奇治療是一家利用其臨床階段微生物組治療公司以人為本的發現® 開發一類新型口服生物藥物的平台。憑藉開發完整和有針對性的微生態療法的能力，芬奇正在推進豐富的候選產品線，旨在滿足各種未滿足的醫療需求。芬奇的主要候選人 CP101 正在進行後期臨床開發，用於預防復發性困難感染並已獲得美國食品和藥物管理局頒發的突破性療法和快速通道名稱。Finch 還為患有自閉症譜系障礙和重大胃腸道症狀的兒童開發 FIN-211。Finch 與武田建立了合作夥伴關係，專注於開發炎性腸病的靶向微生物群療法。芬奇定期在其網站上發布對其投資者可能很重要的信息，網址為。芬奇鼓勵投資者定期諮詢其網站的「投資者和新聞」部分。
Human-First Discovery® is a registered trademark of Finch Therapeutics Group, Inc.
以人為本的發現®是芬奇治療集團有限公司的註冊商標。
Investor Contact:
投資者聯絡人：
Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com
斯蒂芬·賈
吉爾馬丁集團
(858) 525-2047
stephen@gilmartinir.com
Media Contact:
媒體聯絡人：
Jenna Urban
Berry & Company Public Relations
(212) 253-8881
jurban@berrypr.com
珍娜城市
貝瑞公司公共關係
(212) 253-8881
jurban@berrypr.com
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧